Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Influence of TP53 Arg72Pro and 16bp Duplication Polymorphisms on Risk of Breast Cancer in Iran

  • Gohari-Lasaki, Sahar (Department of Medical Genetics, School of Medicine, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Gharesouran, Jalal (Department of Medical Genetics, School of Medicine, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Ghojazadeh, Morteza (Department of RDCC, School of Medicine, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Montazeri, Vahid (Department of General Surgery, School of Medicine, Hematology and Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Ardebili, Seiied Moitaba Mohaddes (Department of Medical Genetics, School of Medicine, Hematology and Oncology Research Center, Tabriz University of Medical Sciences)
  • Published : 2015.04.14
Download PDF
⟨ Previous Next ⟩

Abstract

TP53 is assumed to be a very important tumour suppressor gene, as illustrated by recent reports that have shown effects of its polymorphisms on breast cancer risk. Arg72Pro and PIN3(16bp duplication) polymorphisms are proposed to have an effective role in structural changes of p53 and have therefore attracted interest as a risk factor for breast cancer in different populations. The aim of this study was to examine and determine whether p53 codon 72 and PIN3 Ins16 bp may be associated with an increased risk for breast cancer in female patients from the northwest of Iran. Genotyping was performed by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) method for a total of 100 women with breast cancer and 100 healthy women without any background of cancer, focusing on the TP53 Arg72Pro-16Del/Ins haplotypes and the combined genotypes. The results in this study established no statistical significant distinctions between the genotypes and a llele frequency were found for Arg72Pro and PIN3 Ins 16 bp polymorphisms between patients and controls.

Keywords

References

  1. Ainsley W and James H (1997). Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer:a meta-analysis. Environ Health Perspect, 4, 919-26.
  2. Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, et al (2011). P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol, 28, 709-15. https://doi.org/10.1007/s12032-010-9505-4
  3. Bellini MF, Cadamuro AC, Succi M, Proenca MA, et al (2012). Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomedicine Biotechnol, 2012, 89196.
  4. Bergamaschi D, GascoM, Hiller L, et al (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402. https://doi.org/10.1016/S1535-6108(03)00079-5
  5. Berrada N, Amzazi S, Ameziane-El-Hassani R, et al (2013). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder cancer in Moroccan patients. Clin Cancer Invest J, 1, 302-6.
  6. Costa S, Pinto D, Pereira D, et al (2008). Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC cancer. 8, 32. https://doi.org/10.1186/1471-2407-8-32
  7. Guleria K, Sharma S, Manjari M, et al (2012). p.R72P, PIN3 Ins16bp polymorphisms of tp53 and ccr5?32 in north indian breast cancer patients. Asian Pac J Cancer Prev, 13, 3305-11. https://doi.org/10.7314/APJCP.2012.13.7.3305
  8. Hrstka R, Beranek M, Klocova K, et al(2009).Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Reports, 22, 1205-11
  9. Hu Z, Li X, Yuan R, et al (2010). Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat, 120, 705-14. https://doi.org/10.1007/s10549-009-0488-9
  10. Oliveira A, Ross J, Fletcher J (2005). Tumor suppressor genes in breast cancer, Am J Clin Pathol, 124, 16-28.
  11. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Communicat, 3, 389-92. https://doi.org/10.1006/mcbr.2000.0241
  12. Samson M, Swaminathan R, Rama R, et al (2007). Role of GSTM1 (null/present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer - a case control study from South India. Asian Pac J Cancer Prev, 8, 253-7.
  13. Sharma S, Sambyal V, Guleria K, et al (2014). TP53 polymorphisms in sporadic north indian breast cancer patients. Asian Pac J Cancer Prev, 15, 6871-9. https://doi.org/10.7314/APJCP.2014.15.16.6871
  14. Siddique M, Balram C, Fiszer-Maliszewska L, et al (2005). Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev, 14, 2245-52. https://doi.org/10.1158/1055-9965.EPI-05-0153
  15. Sjalander A, Birgander R, Hallmans G, et al (1996). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-6. https://doi.org/10.1093/carcin/17.6.1313
  16. Vijayaraman K, Veluchamy M, Murugesan P, et al (2012). p53 exon 4 (codon 72) polymorphism and exon 7 (codon 249) mutation in breast cancer patients in southern region (Madurai) of Tamil Nadu. Asian Pac J Cancer Prev, 13, 511-6. https://doi.org/10.7314/APJCP.2012.13.2.511
  17. Wang-Gohrke S, Rebbeck TR, Besenfelder W, et al (1998). p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res, 18, 2095-9.
  18. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer Implications. Nat Rev Cancer, 9,95-10. https://doi.org/10.1038/nrc2584
  19. Zhou X, Gu Y, Zhang S (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a huge review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14. https://doi.org/10.7314/APJCP.2012.13.10.4909

Cited by

  1. Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy vol.43, pp.12, 2016, https://doi.org/10.1007/s11033-016-4072-1
  2. “p53 Polymorphism at Codon 72 and Breast Cancer” - Letter vol.22, pp.1, 2017, https://doi.org/10.15430/JCP.2017.22.1.55
  3. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case–control investigation vol.23, pp.1, 2018, https://doi.org/10.1186/s40001-018-0345-6